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Lymphocyte activation is accompanied by increased adhesiveness and motility. 
Although  specific  antigen  may  be  used  to  stimulate  increased  adhesiveness, 
stimulated lymphocytes show a  generalized increased adherence to cells lacking 
specific antigen.  Cells cultured  in  the  MLR acquire  the ability to adhere  to a 
wide variety of tumor cell types. There is no MHC restriction  in this adhesion, 
although species specificity has been shown (1). Adhesion of lymphocytes to one 
another  can  also  be  measured  as  cluster  formation,  i.e.,  aggregation.  After 
autologous MLR or periodate stimulation, 5-35% of the viable lymphocytes are 
found in clusters (2).  Lymphocytes isolated from clusters by vigorous vortexing 
are found to readily reaggregate.  Cluster formation is also induced by phorboi 
esters. Within  15 rain,  human  PBL show uropod formation, and within 30 min 
exhibit hairy surface projections, ruffled membranes, and begin aggregating (3). 
Similar  aggregation  is  seen  with  monocytes (3) and  some leukocyte cell  lines, 
including EBV-transformed B lymphocytes (4). Both B lymphocytes and the Lyt- 
2 + and Lyt-2- subsets of T  lymphocytes have been shown to participate in cluster 
formation (2).  Despite the obvious relevance of changes in lymphocyte adhesive- 
ness to immune cell interactions,  the cell surface molecules mediating adhesive- 
ness by stimulated lymphocytes have not been defined. 
Previous studies have shown that mAbs to the lymphocyte function-associated 
1 (LFA-1)I molecule inhibit the effector-target adhesion step of CTL-mediated 
killing (5), and a wide variety of other adhesion-dependent  leukocyte functions, 
including  antigen-specific  T-B  cell  cooperation,  antigen-specific  and  mitogen 
proliferative responses (6), natural  killing,  and antibody-dependent cellular cy- 
totoxicity by K cells and granulocytes (7). Lymphocytes from patients with genetic 
deficiency of LFA-1 show diminished activity in adhesion-dependent functional 
assays (8-10).  These findings  suggested that  LFA-1  cooperates with a  number 
of different  specific cell  surface receptors  in  heterotypic  cell-cell  interactions. 
LFA-1 is a leukocyte cell surface glycoprotein with an c~L subunit of 180,000 Mr 
and/3 subunit of 95,000 Mr. 
Here we have investigated the role of LFA-1 in the increased adhesiveness of 
phorbol ester-stimulated leukocytes. Phorbol esters are analogues of diacylglyc- 
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erol, an intracellular second messenger which mediates activation or differentia- 
tion of lymphocytes and monocytes and can mimic the effects of certain physio- 
logic  stimuli  (11-13).  We  report  that  antibodies  to  LFA-1  specifically  inhibit 
phorbol ester-stimulated homotypic aggregation by B cell, T  cell and monocytic 
cell lines, and by PBL. Studies with cell lines from individuals genetically deficient 
in LFA-1 confirm these findings, and show that while LFA-1 mediates homotypic 
cell  interactions,  this  process  is not  mediated  by like-like  interactions  between 
LFA-1  molecules.  The cellular physiology of aggregation has been investigated 
by techniques including time-lapse videomicroscopy. The results show that LFA- 
1 is a  molecule of general  importance in phorbol ester-stimulated  adhesion  by 
lymphocytes and monocytic cells. 
Materials and  Methods 
Cell Lines.  JY  EBV-transformed  B  lymphoblastoid cells  were  maintained  in  RPMI 
1640 medium supplemented with  10% FCS and 50 #g/ml gentamycin (Gibco Laborato- 
ries, Grand Island, NY) (complete medium). EBV-transformed B-cell lines were established 
and maintained as previously described  (14)  using peripheral blood mononuclear cells 
from normal individuals, patients who genetically lack membrane LFA-1, and heterozy- 
gote relatives of these patients (8). 
mAb and F(ab')2 and Fab' Fragments.  The mouse IgG1 TS1/22 and TS1/18 mAb to 
the human LFA-1 aL and/3 subunits, respectively (15),  and the TS2/9 anti-LFA-3 mAb 
(16)  were  obtained  as  previously  described.  The  species-specific anti-HLA-A,B  mAb 
W6/32 has been described (17). A panel of 115 putatively anti-myeloid mAbs that reacted 
with many different types of surface antigens, some of which were on lymphoid cells, was 
obtained in the Second  International  Workshop on Human  Leukocyte Differentiation 
(l 8).  F(ab')2 of TS1/22  were made using preactivated thiol-free papain as described by 
Parham et al. (19). Fab' were made using cysteine reduction of F(ab')~ (19). 
Qualitative  Aggregation Assay.  Cells  lines  were  washed  two  times  with  RPMI  1640 
containing 5  mM  Hepes buffer (Sigma Chemical Co., St.  Louis) and resuspended  to a 
concentration of 2 ×  106 cells/ml. Added to flat-bottomed, 96-well microtiter plates (No. 
3596; Costar, Cambridge, MA) were 50 #l of appropriate mAb supernatant or 50 #1 of 
complete medium with or without purified mAb, 50 #1 of complete medium containing 
200  ng/ml  of PMA  (Sigma Chemical  Co.)  where  necessary, and  100  /~1 of cells at a 
concentration of 2 x  I 0" cells/ml in complete medium. This yielded a final concentration 
of 50 ng/ml PMA and 2 X 10 ~ cells/well. Cells were allowed to settle spontaneously and 
the degree of aggregation was scored at indicated time points. Scores ranged from 0 to 
5+ where 0 indicated that essentially no cells were in clusters;  1+ indicated <10% of the 
cells  were  in  aggregates;  2+  indicated  that  <50%  of the  cells  were  aggregated;  3+ 
indicated that up to 100% of the cells were in small, loose clusters; 4+ indicated that up 
to  100% of the cells were aggregated in larger clusters; and 5+ indicated that  100% of 
the cells were in large, very compact aggregates. 
Quantitative  Aggregation Assay.  Reagents and cells were added  to  5  ml polystyrene 
tubes (No. 2054; Falcon Labware, Oxnard, CA) in the same order as above. Tubes were 
placed in a rack on a gyratory shaker at 37°C. After  1 h at 200 rpm (unless otherwise 
specified), 10 tA of the cell suspension were placed on a hemocytometer and the number 
of free  ceils  was  quantitated.  Percent  aggregation  was  determined  by  the  following 
equation:  Percent aggregation =  100  x  [1  -  (number of free cells)]/(number of input 
cells),  where  number  of input  cells  is  the  number  of cells  per  ml  in  a  control  tube 
containing only cells and complete medium that was not incubated, and number of free 
cells equals the number of nonaggregated cells per ml from experimental tubes. 
FACS.  JY cells were washed three times with RPMI 1640 and stained with mAb using 
indirect immunofluorescence according to Kfirzinger et al. (20).  As control, a nonspecific 
IgG was substituted in the first step. FITC conjugated goat anti-mouse IgG with heavy 
and light chain reactivity (Zymed) was the indirect reagent.  Cells were analyzed on an 1134  PHORBOL-STIMULATED  LEUKOCYTE  ADHESION 
Epics  V  flow  cytometer.  Results  are  expressed  as  linear  fluorescence intensity after 
subtraction of control fluorescence (specific linear fluorescence). 
Capping Experiments.  Cells  were preincubated with PMA at 37°C for 5 min before 
staining where appropriate. Cells were then stained by indirect immunofluorescence in 
test tubes (No. 2054; Falcon Labware) using the same protocol as above while held on ice 
or at 4 °C throughout the staining and washing protocol. Following the final wash,  cells 
were resuspended to a concentration of 107/ml  in complete medium that was preheated 
to 37°C, and the tubes were incubated at 37°C. At the prescribed time points, 100 t~i of 
cell suspensions were collected and fixed with an equal volume of 2% paraformaldehyde 
on ice to prevent further capping. Cells  showing fluorescence on less than 50% of the 
membrane periphery were considered to have capped.  In  coaggregation experiments, 
cells were stained with 6-carboxyfluorescein diacetate (Behring Diagnostics, San Diego, 
CA) (21). 
Time-Lapse Video Microscopy Recording.  Cells were placed in a microtiter plate as in the 
qualitative assay. The well was sealed with clear tape and the plate was put on ice for 15 
min while the cells settled to the bottom of the well. The plate was then placed on an 
inverted microscope (Carl Zeiss, Thornwood, NY) equipped with a Zeiss video recording 
camera, and hot air was blown around the plate to maintain a temperature of about 37°C. 
Time-lapse recordings were made at a rate of 1 frame/s. 
Results 
PMA Stimulates Aggregation of  JY Cells.  Cells from the EBV-transformed line 
JY were found to aggregate in response to PMA using two different assays.  A 
qualitative assay in which JY cells were allowed to aggregate on the bottom of a 
96-well microtiter plate showed that although some adhesion of  JY cells occurred 
in the absence of PMA, in its presence much larger clusters formed, and cluster 
formation was more rapid and reproducible (Fig.  1 A and data not shown). Time- 
lapse  video recording showed  that JY  cells on  the  bottom  of microtiter wells 
were motile and exhibited active membrane ruffling and pseudopodia movement. 
Contact between the pseudopodia of neighboring cells often resulted in cell-cell 
adherence. If adherence was sustained,  the region of cell contact moved to the 
uropod.  Contact  could  be  maintained  despite  vigorous  cell  movements  and 
tugging of the cells in opposite directions. The primary difference between PMA- 
treated and untreated cells appeared to be in the stability of these contacts once 
they were  formed.  With  PMA,  clusters  of cells developed,  growing  in  size as 
additional  cells adhered at their periphery. At first clusters were flattened out 
along the bottom of the well with a  thickness of only one or a  few cells. As the 
clusters grew in size, there was a  dramatic change in the shape of the cluster as 
most of the cells lifted off the bottom of the well and the cluster assumed  the 
shape  of a  roughly  spherical  ball  of cells.  T~is  change  suggests  that  cell-cell 
adhesivity  is  stronger  than  cell-substrate  adhesivity.  After  cluster  formation, 
vigorous  cell  membrane  ruffling continued,  with  little  change  in  the  relative 
position of individual cells within the cluster.  In video timeqapse, this gave the 
cluster the appearance of a heaving mass. 
As  a  second means  of measuring  adhesion,  a  quantitative assay was  used  in 
which  cell  suspensions  were  shaken  at  200  rpm  for  2  h,  transferred  to  a 
hemocytometer, and cells not in aggregates were enumerated. In the absence of 
PMA, 42% (SD =  20%, n  =  6) of  JY cells were in aggregates after 2 h, while JY 
cells incubated under identical conditions with 50 ng/ml of PMA had 87% (SD 
=  8%, n  =  6) of the cells in aggregates.  Kinetic studies of aggregation showed ROTHLEIN AND SPRINGER  1135 
FIGURE 1.  Photomicrographs  of aggregation  and its inhibition by anti-LFA-1.  JY cells  were 
incubated with PMA (A) or with PMA + anti-LFA-1 (B) in the qualitative assay for 30 rain. 
that  PMA enhanced the rate and magnitude of aggregation at all time points 
tested (Fig. 2). 
Anti-LFA-1 mAbs Inhibit PMA-induced Aggregation of  JY Cells.  Since LFA-1 has 
been implicated in lymphocyte adhesion (9), we looked at its role in the PMA 
induced  aggregation  of JY  cells.  The  effects  of anti-LFA-1  mAb  on  PMA 
induced-JY cell aggregation was assessed in both the quantitative and qualitative 
assays. 
Anti-LFA-1  a  chain  (TS1/22)  and  /3 chain  (TS1/18)  mAb inhibited  PMA- 
induced aggregation of  JY cells by 90 and 85%, respectively (Fig. 3). In contrast, 
anti-LFA-3 (TS2/9) and anti-HLA (W6/32) mAb had no effect on aggregation. 
These findings were confirmed in  the qualitative assay, mAb directed against 
either the a  or/3 subunit of LFA-1  inhibited the formation of aggregates of  JY 
cells assayed with and without PMA. One representative experiment is shown in 
Fig.  1, which shows inhibition of phorbol ester-stimulated aggregation by anti- 
LFA-1  /3 mAb. In a  blind screening of a  panel of 115  mAbs directed to many 
different types of leukocyte antigens, only and all seven mAb with anti-LFA-1 a 
or/3 chain reactivity inhibited PMA-induced aggregation (Table I). 
To determine whether inhibition of aggregation was independent of effects 
mediated by the Fc portion or by antibody bivalency, F(ab')2 and Fab' fragments 
of the TS1/22 anti-LFA-la mAb were tested. Both fragments inhibited PMA- 
induced JY cell aggregation (Fig. 4). Since about  10 times more Fab' fragment 
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FIGURE 2.  Kinetics of aggregation. Aggregation in the absence (X) or presence of 50 ng/ml 
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FIGURE  3.  Anti-LFA-1 mAb specifically inhibits aggregation. The indicated mAbs (50 pl of 
tissue culture supernatant)  were added at  the initiation of quantitative aggregation assays. 
Values are one of six representative experiments. 
of the preparations was examined to rule out the presence of residual F(ab')2 in 
the Fab' preparation.  Non-reducing SDS-PAGE of 0.5 pg of F(ab')2 (Fig. 4, lane 
1) and  5.0  pg  of Fab'  (Fig.  4,  lane 2)  showed no  contamination  of the  Fab' ROTHLEIN AND  SPRINGER 
TAnLE  I 
mAb That Inhibit PMA-induced Aggregation 
mAb inhibiting  Specificity* 
aggregation 
TS1/22  LFA-1 (a) 
MHM24  LFA-1 (a) 
TS1/18  LEA-l, Mac-l, p150,95 (~3) 
MHM23  LFA-1, Mac-l, p150,95 (/~) 
60.3  LFA-I, Mac-l, p150,95 
CLB-54  LFA-I, Mac-l, p150,95 
115 mAb in the myeloid panel of the Second International  Leukocyte 
Workshop were tested blind at a final ascites dilution  of 1:150 in the 
qualitative PMA-stimulated JY aggregation  assay. Inhibitory mAb (re- 
ducing aggregation from 5+ to 1+ or -) are shown. 
*  Sanchez-Madrid et al. (16), Springer and Anderson (19), and Hildreth 
et al. (38). 
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FIGURE 4.  F(ab')~  (X) and Fab' (O) fragments of LFA-1 mAb inhibit aggregation.  TS1/22 
mAb fragments were included in the quantitative aggregation  assay. Inset: SDS 10% PAGE 
under nonreducing  conditions of 0.5 ug E(ab')~ (lane 1) and 5 #g Fab' (lane 2) of TS1/22 
LFA-1 mAb. 
preparation by F(ab')2. This shows that monovalent Fab' LFA-1 mAb can inhibit 
aggregation, and suggested that the differing inhibitory activities of F(ab')z and 
Fab' fragments is due to differences in avidity between bivalent and monovalent 
fragments. 
EBV-transformed Cells from Patients Lacking LFA-1, Mac-l, and p150,95 Do Not 
Self-aggregate.  As a  second, independent means of testing the functional impor- 
tance  of LFA-1,  PMA-stimulated  aggregation  of LFA-1-  cells  was  examined. 
EBV-transformed  B  lymphoblastoid  cell  lines  have  been  established  in  our 
laboratory from patients  who are genetically deficient  in  surface expression  of 
the  LFA-1,  Mac-l,  and  p150,95  glycoproteins  (14).  Lines  established  from 
severely and  moderately deficient patients expressed ~<0.1  and  3%  of normal 
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FIGURE 6.  Coaggregation between LFA-1- and LFA-1  +  cells. Carboxyfluorescein  diacetate- 
labeled EBV-transformed  cells  (104) as designated in the figure were mixed with 105 unlabeled 
autologous cells (solid bars) orJY cells (open bars) in the presence of PMA. After 1.5 h in the 
qualitative assay, the labeled cells in aggregates or free were enumerated using an inverted 
fluorescent microscope  (> 100 fl+ cells were counted). The percentage of fluorescent (fl+) cells 
in aggregates is shown. One representative experiment of two is shown. 
healthy, heterozygote relatives and from normal subjects. The latter lines express 
LFA-1, but not the related Mac-1 or p150,95 molecules (15). There was little if 
any aggregation of LFA-1- EBV-transformed cells from two different severely 
deficient  patients  (Fig.  5,  B  and  C)  or  three  different  moderately  deficient 
patients (Fig. 5, E-G). In contrast, EBV-transformed LFA-1 + cells from healthy 
heterozygote siblings (Fig. 5, D and H) and a healthy control (Fig. 5A) aggregated 
strongly. 
Cells  from LFA-l-deficient Patients Aggregate with  JY Cells.  It was of interest to 
determine  whether  LFA-l-deficient lymphoblasts,  which  could not aggregate 
with  themselves,  could coaggregate  with  LFA-1 + cells.  Fluorescein diacetate- 
labeled normal or patient cells were mixed in a  1:10 ratio with autologous or JY 
cells, and the percentage of fluorescein-labeled cells in aggregates was determined 
(Fig.  6).  An  LFA-1 + cell  line aggregated well with itself and with JY.  LFA-1- 
deficient EBV lines showed little self-aggregation, confirming the results in Fig. 
5. However, LFA-1- patient cells coaggregated well with LFA-1 + JY cells. 
Anti-LFA-1 Can Disrupt Preformed Aggregates.  To determine whether LFA-1 
was important only in forming aggregates, or also in their maintenance, LFA-1 
mAb were added  to preformed aggregates (Table  II).  As shown above,  there 
was strong aggregation of JY cells after 2 h  in the presence of PMA (3+ to 5+ 
aggregation in the qualitative assay). When anti-LFA-1 was added to wells at this 
time, and aggregation was assayed 16 h later, we found it was strongly disrupted. 1140  PHORBOL-STIMULATED LEUKOCYTE  ADHESION 
TABLE II 
Ability of Anti-LFA-1 mAb to Disrupt Preformed PMA-induced JY 
Cell Aggregates 
Aggregation score 
Exp.  18 h 
2 h* 
-mAb  +mAb 
1  4+  4+  1+* 
2  3+  4+  1+  ~ 
3  5+  5+  1+ a 
Aggregation in the qualitative microtiter plate assay was scored visually. 
With anti-LFA-1 present througbout the assay period, aggregation was 
<_1+. 
* Amount of aggregation just before addition of mAb at 2 h. 
* TSI/18 + TS1/22. 
0 TSI/18. 
m  TS1/22. 
TABLE III 
Effect of Cytochalasin B on PMA-induced JY Cell Aggregation and Disruption  of Preformed 
Aggregates with Anti-LFA-1 
Additions  PMA induced JY cell 
aggregation 
Oh  1.5h  lh  3.5h  18h 
None  None  3+  5+  5+ 
Anti-LFA-  1  None  1  +  1  +  1  + 
Cytochalasin B  None  0  0  0 
None  Anti-LFA-1  3+  2+  1  + 
None  Cytochalasin B  3+  5+  4+ 
None  Anti-LFA-1 + Cytochalasin B  3+  5+  4+ 
Additions of TS 1/18 were made and aggregation scored at the times shown relative to the initiation 
of PMA-stimulated aggregation in the qualitative microtiter plate assay. 
Time-lapse video recording confirmed that addition of LFA-1 mAb to preformed 
aggregates began to cause disruption within 2 h. After addition of LFA-1  mAb, 
pseudopodial movements and changes in shape of individual  cells within aggre- 
gates  continued  unchanged.  Individual  cells  gradually  dissociated  from  the 
periphery of the aggregate;  by 8  h  cells were mostly dispersed.  By video time- 
lapse, the disruption of preformed aggregates by LFA-1  mAb appeared equiva- 
lent to the aggregation process in the absence of LFA-1 mAb running backwards 
in time. 
PMA-stimulated JY  cell  aggregation  was  inhibited  when  cytochalasin  B  was 
added  at  the  initiation  of the  aggregation  (Table  III, line  3).  However,  when 
cytochalasin  B  was added  after  1.5  h,  by which  time  aggregates  had  formed, 
aggregates were not disrupted  (Table  III, line  5).  Time-lapse video recordings 
revealed that cytochalasin B  caused JY cells to round  up with a  loss of motility, 
and the heaving cell aggregates immediately became placid.  When cytochalasin HLA 
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FIGURE 7.  Surface antigen expression with and without stimulation by PMA. JY cells incu- 
bated for 1 h without PMA (m) and with PMA (k~), or patient 2 cells incubated for 1 h without 
PMA (11) and with PMA (Fq) were stained with LFA-1 /~ chain mAb, TS2/9 LFA-3 mAb, or 
W6/32  HLA  mAb, an  excess of FITC-goat  anti-mouse  Ig, and  then subjected to flow 
cytometry. The fluorescence intensity due to specific staining is shown. 
B was added together with LFA-1  mAb at  1.5 h, aggregation was not reversed 
(Table III, compare lines 4 and 6), The failure of anti-LFA-1  to disrupt aggre- 
gation when added simultaneously with cytochalasin B  may be because motility 
is required for disaggregation in this assay system. 
Effect  of PMA  on  LFA-I  Expression,  LFA-1  Capping,  and Motility  of JY Cells. 
While it is clear that PMA and LFA-1  facilitate the aggregation of JY cells, the 
role  of each  of these  molecules  remained  unclear.  One  mechanism  by which 
PMA might stimulate LFA-l-dependent JY cell aggregation would be by increas- 
ing LFA-1  expression on the cell surface.  However, immunofluorescence flow 
cytometry showed  that  there was  no change  in  LFA-1  expression on JY  ceils, 
and showed that PMA did not induce expression on patient cells (Fig.  7).  PMA 
also had little effect on LFA-3 and HLA expression. 
Patarroyo et al.  reported that  Con  A  receptors more rapidly cap  on  PMA- 
treated PBL (22). We tested whether PMA-induced  LFA-1  to cap faster on JY 
cells.  Cells  were  reacted  with  LFA-1  mAb,  then  FITC  anti-mouse  IgG,  and 
warmed to 37 ° C. LFA-1 was capped somewhat more rapidly on PMA-stimulated 
JY cells, although the molecule capped quickly both in the presence and absence 
of PMA (Fig. 8). 
It was next tested whether cell motility was affected by PMA or LFA-1  mAb. 
A  sparse population of  JY cells on the bottom of a microtiter well was allowed to 
stabilize at  37°C and cell movement was then measured over a  30 min period 
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FIGURE 8.  Representative experiment of kinetics of capping of LFA-1 on JY  cells.  One 
representative experiment is shown of  JY cells cultured in the absence (X) or in the presence 
of 50 ng/ml PMA (O). 
TABLE  IV 
Lack of Effect of LFA-1 mAb or PMA on JY Cell Motility 
Cell movement (ttm)* 
Treatment 
No mAb  LFA-1 mAb 
No PMA  75 :l: 32  97 4- 47 
PMA  67 4- 48  57 4- 17 
3 x  103 cells were centrifuged at 200 rpm in a microtest plate for 2 rain 
in the presence or absence of PMA and/or anti-LFA-1 mAb (TS 1  ] 18 + 
TS1/22). Wells were then sealed and plates were incubated for 30 rain 
at 37°C  to allow temperature equilibration. Cells were videotaped in 
time lapse for 30 min and the final distances traveled were calculated. 
* Average of five randomly chosen cells/treatment 4- standard deviation. 
significant  difference  in  cell  movement  whether  anti-LFA-1  and/or  PMA  was 
added  to the wells (Table IV). 
Divalent  Cation  Requirement for  PMA-induced JY  Cell  Aggregation.  LFA-1- 
dependent  adhesions between cytotoxic T-cells and targets require the presence 
of Mg  +2  (23).  PMA-induced  JY  cell aggregation  was  tested  for  divalent cation 
dependence.  JY  cells failed to aggregate  in  Ca +~- and  Mg+2-free  HBSS  (Table 
V). Addition of Mg  +2 supported aggregation at concentrations as low as 0.3 mM. 
Addition of Ca  +2 alone had little effect.  Ca  +2 augmented  the ability of Mg  ÷2 to 
support  PMA-induced  aggregation.  When  1.25  mM  Ca +2  was  added  to  the 
medium,  Mg  +2 concentrations as low as 0.02  mM supported aggregation. These 
data  show  that  PMA-induced  aggregation  of JY  cells requires  Mg  +2,  and  that 
Ca  +2 is insufficient but can synergize with  Mg  +z. ROTHLEIN AND SPRINGER 
TABLE V 
Divalent Cation Requirement  for PMA-stimulated JY Cell Aggregation 
1143 
Divalent  Divalent cation concentration (mM) 
cation  5.00  2.50  1.25 0.63 0.32  0.16  0.08  0.04  0.02  0.01  0.005 0.0025 
Mg  ++  4+  4+  4+  3+  3+  1+  0  0  0  0  0  0 
Ca  ++  1  +  1  +  +  +  0  0  0  0  0  0  0  0 
1.25 mM Ca  ++  ND  ND  4+  4+  3+  3+  3+  3+  3+  2+  1+  0 
+ Mg  ++* 
The qualitative assay in microtiter plates was scored. MgCI~  and CaCI2 were added to Mg  +~- and 
Ca+Lfree HBSS. 
* The concentration of Mg  +÷ was varied. 
TABLE VI 
PMA Stimulation ofU937 and SKW3 Aggregation and its Inhibition 
by LFA-I mAb 
Cell culture 
Aggregation* 
Control  LFA-1  mAb* 
U937 + PMA  0  ND 
Differentiated U9370 + PMA  3+  0 
SKW3  1+  0 
SKW3 + PMA  3+  0 
* Measured in the qualitative assay after 2-4 h. 
* TS1/22 anti-LFA-1 a. 
0 Differentiated by culture for 3 d in 2 ng/ml PMA. 
PMA-stimulated  Aggregation  of Other  Types  of Leukocytes.  The  above  studies 
were performed with B cell lines. In a survey of the LFA-1 dependence of PMA- 
stimulated aggregation by other cell types,  the myelomonocytic U937 cell  line 
and the T  cell line SKW-3 were tested (Table VI). Undifferentiated U937 cells 
failed to aggregate in the presence or absence of a short-term exposure to PMA 
(Table  VI).  U937 cells that were differentiated to monocyte-like cells by culti- 
vation in  2  ng/ml  PMA for  3  d  vigorously aggregated.  This  aggregation was 
inhibited  by anti-LFA-1  a  chain mAb. Aggregation of the T  cell line,  SKW-3, 
was stimulated by PMA and inhibited by anti-LFA-1 (Table VI). Unlike SKW-3, 
the LFA-1 + T  lymphoma Jurkat did not aggregate in the presence of PMA (not 
shown). 
The importance of LFA-1 in aggregation of normal cells was tested with PBL. 
Lymphocytes did  not  aggregate  unless  PMA  was  added  (Table  VII).  PMA- 
stimulated aggregation was inhibited 78% by anti-LFA-1 a  mAb. Similar inhibi- 
tion  was  obtained  with  anti-LFA-1  a  and  /3  mAb,  and  with  peripheral  blood 
mononuclear cells (not shown). 
Discussion 
We have found that  LFA-1  plays a  critical  role  in  phorbol ester-stimulated 
lymphoid cell adhesiveness. Phorbol esters stimulate the protein kinase C cascade, 
and  mimic  in  part  the  physiologic effects of lymphocyte activation by specific 
agents such as antigen (12). This model system of lymphocyte stimulation allowed 1144  PHORBOL-STIMULATED  LEUKOCYTE  ADHESION 
TABLE VII 




Control  LFA-1 mAb 
Without PMA  0  0 
With PMA  46  10 
Ficoll-Hypaque-purified human peripheral blood mononuclear cells were 
depleted of monocytes by adherence for 2 h to tissue culture plates. Latex- 
ingesting cells were reduced from 16 to 3% of total cells by the adherence 
step.  Aggregation was  tested in  the quantitative assay,  with or without 
TS1/22 mAb. 
measurement of the component of lymphocyte adhesiveness which is independent 
of specific receptor-ligand interactions. 
PMA-stimulated aggregation  by B, T, and monocyte cell lines and peripheral 
blood iymphocytes was completely or largely inhibited by mAb to the cell surface 
LFA-1 molecule. The weaker spontaneous aggregation of  JY cells in the absence 
of PMA was also inhibited by LFA-1 mAb, in agreement with brief reports from 
our (10) and other labs (24, 25) and a brief communication onJY cell aggregation 
which appeared while this manuscript  was in preparation  (28). We showed that 
aggregation is blocked by LFA-1 mAb monovalent Fab' fragments as well as by 
F(ab')2 fragments and  IgG.  Antibodies to both the  a  and/3  subunit of LFA-1 
inhibited  aggregation.  Antibodies  to  several  other  surface  molecules  did  not 
inhibit. 
Independent  evidence for the importance  of LFA-1  in activation-dependent 
lymphoid cell adhesion  came  from  studies  on  EBV  lines  from patients  with  a 
heritable deficiency of the LFA-1, Mac-1, and p150,95 glycoproteins. Since EBV 
lines established from healthy individuals are  LFA-1 ÷, Mac-l-,  p150,95-,  only 
the deficiency of LFA-1 was relevant to these studies. All LFA-1 deficient lines 
that were tested, from five different patients,  were strikingly deficient in PMA- 
stimulated  aggregation.  Together,  our findings  with  LFA-1  mAb and  patient 
cells provide strong evidence for the biological importance of LFA-1 in stimulated 
lymphoid cell adhesion.  In a  recent report on a  patient  with deficiency of the 
C3bi receptor  (Mac-1  molecule),  a  similar  defect was noted  in  aggregation  of 
EBV-transformed  cells (26).  Although  LFA-1  expression  by this  patient's  cells 
was not characterized, the findings are consistent with out own, since this patient 
may resemble others studied (8) in lacking LFA-1 as well as Mac-1. 
While the LFA-l-dependent interactions studied here are homotypic, they are 
not mediated by LFA-1 like-like interactions, i.e., by binding of LFA-1 molecules 
on one cell to LFA-1 molecules on another cell. This was shown by the finding 
that while LFA-1- cells did not self-aggregate, they could coaggregate with LFA- 
1  + cells. With like-like interactions ruled out, two possible molecular mechanisms 
remain.  LFA-1 could be a receptor that binds to a distinct ligand on other cells. 
Alternatively,  LFA-1  could  regulate  adhesiveness  indirectly,  for  example,  by 
modulating  the  movement  or  molecular  organization  of  the  membrane  or 
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Previous studies showed LFA-3 mAb block CTL-mediated killing by binding 
to target cells (27),  suggesting that LFA-3 may function as a  ligand. However, 
LFA-3 does not appear to be a  iigand for LFA-1, because anti-LFA-3 did not 
inhibit either spontaneous adhesion by JY cells or PMA-stimulated adhesion by 
a variety of cell types. Two other brief reports conflicted with each other on the 
involvement of the LFA-3 molecule in spontaneous JY cell aggregation (25, 28). 
Time-lapse video microscopy showed that cells that are competent for aggre- 
gation are polarized, motile, and exhibit active membrane ruffling and pseudo- 
pod movement. Adhesion between neighboring cells was initiated at pseudopo- 
dial contacts, and the site of adhesion then moved to the uropod. After cluster 
formation, vigorous pseudopodial movements continued. When LFA-1 mAb was 
added to preformed clusters, they dissociated. Both cluster formation and dis- 
sociation  were  inhibited  by  cytochalasin  B.  These  observations  suggest  that 
aggregation is a dynamic process. 
Since many of the  LFA-1 + cell types studied here do not aggregate in  the 
absence of PMA, LFA-1  is required, but not sufficient, for aggregation. PMA 
had little or no effect on the quantity of LFA-1 present on the cell surface and 
stimulated only a  slight  increase in  the rate of LFA-1  capping on EBV  lines. 
Phorbol ester stimulation of the protein kinase C cascade may have effects on 
the cell membrane, cytoskeleton, motility, or other aspects of cell physiology that 
allow adhesiveness mediated by the LFA-1 molecule to be expressed. 
Phorbol ester-stimulated LFA-1-dependent adherence by B, T, and monocyte 
cell lines and PBL may be relevant to specific receptor-stimulated adherence by 
these cells in specific immune interactions. The relevance of LFA-l-dependent 
aggregation to immune reactions is also suggested by its divalent ion require- 
ments. The requirement for Mg  +2 but  not Ca  +2, and the synergistic effect of 
Ca  +2,  are similar to  the divalent cation requirements of the adhesion  step in 
CTL-mediated killing (23).  LFA-1  has previously been found important in  T 
cell, NK cell, and antibody-dependent granulocyte effector cell function, as well 
as in T  helper cell responses (6, 29-32).  LFA-1  was found to participate in the 
effector-target cell conjugation (adhesion) step of CTL-mediated killing (5). 
These previous findings suggest that LFA-1 can cooperate with specific recep- 
tors to increase the effectiveness of specific cell-cell interactions.  The present 
findings clarify these earlier results by showing that LFA-1 is a general leukocyte 
adhesion molecule, and raise an interesting question. Does binding of an effector 
cell to a target cell bearing specific antigen stimulate the effector cell, leading to 
increased LFA-l-dependent adherence? If so,  specific receptor-ligand interac- 
tions themselves need not contribute all the binding energy required for the cell 
interaction, but would trigger an LFA-l-dependent mechanism for amplifying 
the binding energy. Thus, adhesion could be accomplished with a fewer number 
of receptor-antigen interactions and specific antigen recognition would be more 
sensitive.  How  long  LFA-l-dependent  adherence persists  after  physiological 
stimulation  of cells  is  an  important  question  for  further work.  Cloned  CTL 
propagated using antigen stimulation in vitro may be "activated" analogously to 
the PMA-stimulated cells studied here. They form LFA-l-dependent conjugates 
with  both  antigen-specific and  antigen-nonspecific  target  cells,  and  findings 1146  PHORBOL-STIMULATED LEUKOCYTE ADHESION 
suggest that  LFA-l-dependent  adhesion  may precede or occur simultaneously 
with specific antigen recognition (33). 
The findings presented here on the importance  of LFA-1  in homotypic cell 
interactions suggest that  in heterotypic interactions such as CTL-mediated kill- 
ing, LFA-1 on the target cell, as well as on the effector cell, may be functionally 
important. This idea has received support from recent studies on killing by LFA- 
1-deficient  CTL  of LFA-1 ÷ JY target  cells (34).  Killing by CTL  from  several 
moderately deficient patients was inhibited by LFA-1 mAb pretreatment of CTL 
effector or JY  target  cells,  while  killing  by CTL  from  one  severely deficient 
patient was only inhibited by treatment of the target cells. In contrast, in killing 
by LFA-I ÷ CTL, LFA-1 on the CTL effector is much more important than on 
the target cell (27, 29, 34). 
Summary 
Lymphocytes become adherent and aggregate after stimulation with phorbol 
esters such as PMA. Time-lapse video showed that aggregating ceils were motile 
and exhibited vigorous pseudopodial movements. Adhesion sites were initiated 
between pseudopodia of neighboring cells, and then moved to the uropod. PMA- 
stimulated aggregation by EBV-transformed B cell lines, SKW-3 (a T  cell line), 
differentiated U937 (a monocytic line), and blood lymphocytes was inhibited by 
mAbs to LFA-1. A number of different mAb to the LFA-1 a and 3 subunits and 
F(ab')2 and  Fab'  fragments  inhibited  aggregation.  Furthermore,  lymphoblasts 
from normal  individuals,  but not from LFA-l-deficient patients,  aggregated in 
response to PMA. These findings suggest LFA-1  is critically involved in stimu- 
lated lymphocyte adhesion.  LFA-1 expression was not increased by PMA stimu- 
lation,  showing  that  other  mechanisms  regulate  LFA-l-dependent  adherence. 
LFA-1-deficient patient cells were able to coaggregate with LFA-1 ÷ cells, showing 
that aggregation  is not mediated by like-like interactions between LFA-1  mole- 
cules on opposite cells. Aggregation was Mg+~-dependent, inhibited by cytochal- 
asin B, and was reversed when LFA-1 mAb was added to preformed aggregates. 
Previous  findings  suggesting  that  LFA-1  is  important  in  a  wide  variety  of 
leukocyte functions are  elucidated  by this  work,  which  shows that  LFA-1  is a 
general  leukocyte cell adhesion  molecule,  the activity of which is regulated  by 
cell activation. 
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